InsiderPulse
Dashboard

SUPN

Supernus Pharmaceuticals, Inc.

Health CareRussell 2000

Supernus Pharmaceuticals, Inc. insider trading

Supernus Pharmaceuticals, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Rockville, MD. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent SUPN insider transactions

6 insiders traded SUPN on the open market between Mar 05, 2026 and Mar 18, 2026 — 15 sales worth $9M, of which 9 were pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$9M

9 of 15 on a 10b5-1 plan

Net
−$9M
Insiders
6

Open-market purchases (code P) and sales (code S) from Supernus Pharmaceuticals, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every SUPN Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

SUPN insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 10 insiders traded SUPN on the open market: 0 purchases and 62 sales worth $45.3M, 41 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 47 sales ($32.3M), by 9 insiders.

QuarterBoughtSold
Q2 2026——
Q1 2026—−$9.2M17 sales · 11 on a plan
Q4 2025—−$7.4M9 sales · 8 on a plan
Q3 2025—−$15.7M21 sales · 17 on a plan
Q2 2025——
Q1 2025—−$542.2K4 sales · 3 on a plan
Q4 2024—−$12.1M9 sales · 2 on a plan
Q3 2024—−$435K2 sales
Largest sale
−$4.6M of SUPN by Khattar Jack A. (President, CEO · Director) on Nov 07, 2024.

Open-market transactions through Jun 30, 2026most recent first

  • Sensenig Bethany10b5-1

    Director

    −$167K

    Feb 19, 2026

    3,258 sh · $51.27

  • Sensenig Bethany10b5-1

    Director

    −$61.2K

    Feb 19, 2026

    1,217 sh · $50.31

  • Mottola Frank10b5-1

    SVP, Chief Tech. Ops. Officer

    −$757.1K

    Dec 19, 2025

    15,000 sh · $50.47

  • Mottola Frank10b5-1

    SVP, Chief Tech. Ops. Officer

    −$251.1K

    Dec 19, 2025

    5,000 sh · $50.22

  • Bhatt Padmanabh P.

    Sr. VP of IP, CSO

    −$31.6K

    Dec 18, 2025

    710 sh · $44.44

  • Khattar Jack A.10b5-1

    President, CEO · Director

    −$3M

    Oct 09, 2025

    58,371 sh · $50.55

  • Newhall Charles W III10b5-1

    Director

    −$1.2M

    Oct 09, 2025

    23,800 sh · $50.73

  • Khattar Jack A.10b5-1

    President, CEO · Director

    −$78.7K

    Oct 09, 2025

    1,529 sh · $51.46

  • Newhall Charles W III10b5-1

    Director

    −$61.9K

    Oct 09, 2025

    1,200 sh · $51.55

  • Khattar Jack A.10b5-1

    President, CEO · Director

    −$91.5K

    Oct 02, 2025

    1,904 sh · $48.06

  • Khattar Jack A.10b5-1

    President, CEO · Director

    −$1.9M

    Oct 01, 2025

    40,173 sh · $48.07

  • Khattar Jack A.10b5-1

    President, CEO · Director

    −$414.4K

    Sep 30, 2025

    8,588 sh · $48.25

  • Khattar Jack A.10b5-1

    President, CEO · Director

    −$491.5K

    Sep 29, 2025

    10,235 sh · $48.02

  • Khattar Jack A.10b5-1

    President, CEO · Director

    −$1.4M

    Sep 23, 2025

    29,513 sh · $47.23

  • Khattar Jack A.10b5-1

    President, CEO · Director

    −$779.9K

    Sep 22, 2025

    16,587 sh · $47.02

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Supernus Pharmaceuticals, Inc. company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Rockville, MD
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001356576

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought SUPN

What the stock actually did in the 90 days following each open-market purchase

Don't check SUPN — let it ping you

Get told the moment an insider moves on SUPN

Pro watches Supernus Pharmaceuticals, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add SUPN to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track SUPN on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read SUPN insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

OMCLHQYDOCSOSCRALHCASTHBDXTECHCAHCNCCRLCOO
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are SUPN insiders buying or selling?
Between Mar 05, 2026 and Mar 18, 2026, 6 Supernus Pharmaceuticals, Inc. insiders made no open-market purchases and 15 sales worth $9M, a net sale of $9M. 9 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much SUPN stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 10 Supernus Pharmaceuticals, Inc. insiders made no open-market purchases and 62 sales worth $45.3M. 41 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 47 sales ($32.3M). The largest sale was Khattar Jack A. selling $4.6M on Nov 07, 2024.
What was the largest recent SUPN insider trade?
Bhatt Padmanabh P. (Sr. VP of IP, CSO) sold $1.7M of SUPN stock on Mar 16, 2026 at about $50.18 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy SUPN shares?
No open-market purchase by a Supernus Pharmaceuticals, Inc. insider appears in the filings from Mar 05, 2026 to Mar 18, 2026 — every recorded open-market transaction in that period was a sale.
Where does SUPN insider trading data come from?
From the Form 4 filings Supernus Pharmaceuticals, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.